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Summary lodised oil (lipiodol) administered via the hepatic artery localises selectively in primary liver cell
cancers (hepatocellular carcinomas or HCCs) for prolonged periods and has been used as a vehicle for
cytotoxic agents. Despite clinical use, the mechanism of lipiodol retention by tumours has remained unclear,
embolisation ofoil droplets in the tumour vasculature being the prevailing hypothesis. We have investigated the
role of tumour and endothelial cells in lipiodol retention. Human liver tumour (Hep G2) cells and human
umbilical vein endothelial cells in culture were exposed to lipiodol. Light microscopy using selective silver
impregnation stains and transmission electron microscopy revealed lipiodol incorporation by both cell types,
probably by pinocytosis. This was not associated with cellular injury in terms of cell lysis, cell replication or
radio-labelled leucine uptake. Histological analysis of 24 HCCs either surgically resected or discovered
incidentally at liver transplantation (with prior arterial injection of lipiodol) revealed vesicles of lipiodol in the
cytoplasm of tumour cells and endothelial cells lining tumour vessels. Thus, lipiodol is likely to deliver
cytotoxic agents directly into tumour cells and endothelial cells, both in vitro and in vivo. This may also apply
to other lipids and to other human tumours. These findings have significant therapeutic implications.
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Hepatocellular carcinoma currently carries a grim prognosis.
Surgical resection and in selected cases orthotopic liver
transplantation offer the only hope of cure, but over 80%
of patients present with inoperable disease (Okuda et al.,
1985). Lipiodol, an iodinated derivative of poppyseed oil, has
been in use for over a decade as a vehicle for targeted
cytotoxic or radiotherapeutic treatment of unresectable
HCCs. When injected into the hepatic artery the oil is
retained by HCCs for several weeks to over a year, but is
cleared from normal liver parenchyma within 7 days
(Nakakuma et al., 1979). Trials using lipiodol in conjunction
with cytotoxic drugs such as doxorubicin, epidoxorubicin,
aclarubicin, 5-fluorouracil, mitomycin, cisplatin and
SMANCS (a polymer of neocarzinostatin with styrene and
maleic acid), or radioisotopes such as 131I have yielded
improved survival rates (Bhattacharya et al., 1994). Lipiodol
ultra fluid (Laboratoire Guerbet, Roissy Charles de Gaulle,
France) is manufactured by ethyl trans-esterification of
poppyseed oil, and consists of mono- , di- and tri-iodinated
ethyl esters of linoleic (73%), oleic (14%), palmitic (9%) and
stearic (3%) acid (I Chastin Laboratoire Guerbet; personal
communication) with an iodine content of 37-39% by
weight.
Hypotheses attempting to explain lipiodol retention in
HCCs fall into two major categories. One suggests that
lipiodol is retained within the tumour blood vessels, which may
be due to an altered electrostatic charge on the endothelial
cell surface causing lipid adsorption, or impaired exit of lipid
droplets due to altered drainage channels, embolisation being
determined by droplet size. The other proposes that lipiodol
lodges in the extracellular space, as tumour vessels are more
'leaky' than usual, and because lymphatics are absent in
HCCs. Uptake by the reticuloendothelial cells in the liver,
spleen, marrow and lungs is the probable route by which
lipiodol is cleared when administered systemically, and HCCs
may be unable to clear lipiodol because they lack a
reticuloendothelial Kupffer cell component. There have been
relatively few investigations into the role of the tumour cells
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in the retention of lipiodol. We have studied the potential
role of tumour cells in lipiodol retention, in vitro and in three
settings in vivo, in an attempt to answer the following
questions: (1) do tumour cells incorporate lipiodol and if so
by what mechanism? (2) if cellular incorporation of lipiodol
does occur, then is it possible to quantitate the uptake and
modify it? (3) does lipiodol incorporation have any effect on
cancer cells?
Materials and methods
In vitro assessments of cellular interactions with lipiodol were
performed on monolayers of Hep G2 and human umbilical
vein endothelial cells (HUVECs) in culture. Hep G2 is a well
characterised human liver cancer cell line (European
Collection of Animal Cell Cultures: number 85011430)
(Javitt, 1990). HUVECs were used instead of tumour
endothelium. They share a common embryological origin
with hepatic sinusoidal endothelium (Hamilton and Moss-
man, 1976) and also have several surface markers in common
with the tumour endothelium in HCCs, namely Ulex
Europeus Lectin, Factor VIII and QBendlO (Dhillon et al.,
1992). Monolayers of Hep G2 and HUVECs grown on tissue
culture chamber slides were exposed for 4, 8, 24 and 32 h to
culture media containing 1%, 2% and 4% of lipiodol by
volume [in human subjects, bolus injection of 10 ml lipiodol
over a period of 1 min into the hepatic artery, which has an
average flow of 500 ml min-' (Tygstrup et al., 1962) is likely
to yield a lipiodol concentration of 2% in the hepatic arterial
blood reaching the tumour]. The iodised oil which is heavier
than water, initially remained suspended as fine droplets in
the aqueous medium following vigorous agitation and then
settled as droplets on the surface of the cell monolayer.
Following exposure to lipiodol the monolayers were stained
by a silver nitrate impregnation technique adapted from
Arnold et al. (1990). This involved fixation of the cell
monolayer in 10% formaldehyde, removal of excess
formaldehyde by rinsing and soaking overnight in distilled
water, a 1 min rinse with 70% ethanol to remove excess
lipiodol adherent to the surface of the slide and further
rinsing in distilled water. The monolayers were then
immersed in freshly prepared silver nitrate solution (2.5%
in distilled water) for 60 min in the dark at 40C. Excess silver
nitrate was removed by rinsing in distilled water and the
slides were counterstained with Carazzi's haematoxylin. ThisCellular uptake in lipiodol
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technique selectively stains lipiodol a golden brown colour to
the exclusion of endogenous intracellular lipids. The optical
density of the stained monolayers could therefore be expected
to correlate with the degree of lipiodol retention. A
computerised video image analysis system (Williams et al.,
1986) was used to obtain an objective measure of the optical
density of staining and thereby calculate the average staining
intensity per cell (i.e. a reflection of lipiodol accumulation in
each cell).
Assessment of lipiodol retention by tumours in vivo was
carried out in three distinct clinical situations.
(1) Eight patients with solitary resectable HCC received
hepatic arterial injection of a lipiodol-epirubicin emulsion as
adjuvant therapy 1 -3 weeks before surgery. The resected
lesions were stained with 2.5% silver nitrate using a silver
impregnation technique adapted from Arnold et al. (1990).
Formalin-fixed tissue was cut into blocks 1 mm thick and
immersed in distilled water for 18 h to wash out the formalin.
The blocks were then immersed in 2.5% silver nitrate for 1 h
in darkness. Excess silver nitrate was removed by rinsing in
distilled water and the specimens were processed in alcohol
for routine haematoxylin and eosin staining.
(2) The effect of lipiodol without associated cytotoxic agents
was assessed in 37 patients with chronic liver disease who
were given lipiodol at the time of routine hepatic
arteriography before liver transplantation to identify occult
HCCs. When the livers were subsequently removed, they were
sliced (breadloafed) into 1-cm-thick serial sections and soft
tissue radiographs were taken of every slice that contained
any unusual lesion on naked-eye examination. All foci of
lipiodol retention, as judged on soft tissue radiographs, were
sampled for histological analysis. Fifteen hitherto undetected
HCCs were discovered in four of these livers and these were
stained with silver nitrate. However, there was a gap of 1-6
weeks between lipiodol angiography and removal of the livers
at transplantation.
(3) To assess the effect of lipiodol on tumour cells
immediately after injection, 12 livers that had not received
lipiodol before transplantation were flushed with a 20 ml
emulsion of lipiodol (equal volumes of lipiodol and 0.9%
saline agitated before injection) via the hepatic artery ex vivo
within 15 min of removal, while the cells could be considered
hypoxic but still viable and processed in similar fashion
(formalin fixation, serial sectioning, soft tissue radiographs
and silver impregnation of all foci of lipiodol uptake). A
hitherto undetected 3 cm HCC was found in one of these
livers and this avidly took up lipiodol.
Results
Hep G2 and HUVECs monolayers exposed to lipiodol
(n =30) consistently demonstrated intracellular golden brown
vesicles of lipiodol on silver nitrate impregnation (Figure la
and b). In cells unexposed to lipiodol there were no
comparable vesicles. Apart from this, the two groups were
similar in cell numbers, appearances of individual cells and
their nuclei, and the configuration of cells on the surface of
the slide. Transmission electron microscopy (TEM) of Hep
G2 cells exposed to lipiodol revealed unusual multiple
intracellular vesicles (Figure lc). Their appearance and their
consistent absence in the control cells unexposed to lipiodol
indicated that these intracellular vesicles were representative
of incorporated lipiodol or some derivative thereof. Inspec-
tion at high magnification indicated that these were
membrane-bound vesicles, suggesting pinocytosis as a likely
mechanism of incorporation. Some of the vesicles were seen
in association with lysosomes. The presence of these vesicles
was not associated with any evidence of cellular injury.
The optical density of every monolayer exposed to
lipiodol, as quantitated by image analysis, was compared to
the optical densities of the corresponding 'control' mono-
layers (n = 10 for each time period and concentration). For
both cell types in every instance exposure to lipiodol was
associated with an increase in optical density. Hep G2 cells
aI
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Figure 1 Light microscopic appearance of (a) Hep G2 and (b)
HUVECs exposed to 2% lipiodol for 24h showing golden brown
cytoplasmic vesicles oflipiodol. Fixation in formalin was followed
by immersion in distilled water and a rinse in 70% ethanol for 1
min to remove excess lipiodol adherent to the surface.
Monolayers were immersed in fresh 2.5% silver nitrate solution
for 60 min at 4°C in the dark, washed further in distilled water
and counterstained with Carazzi's haematoxylin. Transmission
electron microscopy (c) of Hep G2 cells demonstrated membrane-
bound cytoplasmic vesicles not present in controls.
demonstrated a slow rate of uptake initially followed by
progressive intracellular accumulation. HUVECs showed a
rapid initial uptake, but subsequently the optical densities
diminished, indicating that lipiodol had been excreted or
metabolised by the cells (Figure 2). The rate of cellular
lipiodol uptake also depended on the concentration of
lipiodol in the medium. Lipiodol incorporation had no
statistically significant effect on Hep G2 cell viability
(trypan blue exclusion and lactate dehydrogenase release),
cell numbers (measured by cell counts) and cellular protein
metabolism (3H-labelled leucine uptake).
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1% lipiodol 61.2 ± 11.4 64.7 ± 25.9 57.1 ± 25.6 85.5 ± 25.5
2% lipiodol 74.0 ± 39.5 62.7 ± 17.7 117.4 ± 34.4 152.7 ± 58.1
4% lipiodol 79.7± 35.1 142.6 ± 66.7 118.6 ± 54.2 126.8± 52.1
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Duration of exposure to lipiodol (h)
4 hours 8 h 24 h 32 h
Control 16.4 ± 9.7 7.4 ± 2.9 6.5 ± 5.6 13.9 ± 8.3
1% lipiodol 75.0 ± 69.3 18.9 ± 9.9 51.3 ± 16.4 25.2 ±13.2
2% lipiodol 64.1 ± 25.7 27.1 ± 12.8 35.3 ± 17.3 82.8 ± 45.9
4% lipiodol 112.8± 48.3 69.2± 16.9 191.4± 74.8 130.5± 51.7
Figure 2 Incorporation of lipiodol by (a) Hep G2 and (b) HUVECs quantitated by computer-assisted image analysis: effect of lipiodol
concentrations (E], 1%; 0, 2%; A, 4%; O, control) and duration of exposure on uptake. Figures depict average integrated optical density
(IOD) per cell in monolayers following exposure to lipiodol (silver nitrate stain for lipiodol, counterstained with Carazzi's haematoxylin).
Control monolayers were not exposed to lipiodol. Values in the figures represent arithmetic mean (n = 10) of the IOD, measured in arbitrary
units. Values in the table represent mean IOD+s.d., measured in arbitrary units.
Histological analysis of the eight resected HCCs showed
complete tumour necrosis in one specimen. The other seven
showed droplets of lipiodol localised within a majority of
tumour vessels. The appearances indicated that apart from
being present within the lumen, lipiodol had been
incorporated by the endothelial cells lining these vessels
(Figure 3). Areas of necrosis were seen circumferentially
extending around the vessels that contained lipiodol, which
may represent the cytotoxic effect of epirubicin or a hypoxic
effect following endothelial injury or lipid embolisation. No
comparable changes were present in the 'non-tumour' liver
parenchyma.
Similar observations were made in the HCCs found in
explant livers removed at transplantation. Lipiodol was
present in the lumen of the majority of tumour vessels, in
the endothelial cells lining these vessels and in tumour
cells surrounding these vessels. However, there were few
areas of perivascular necrosis, probably reflecting the fact
that these lesions had received only lipiodol and no
cytotoxic agent. Of particular interest was the one lesion
in an explant liver that was perfused with lipiodol ex vivo
and fixed immediately thereafter. Brown intracellular
vesicles of lipiodol were present in numerous tumour
cells, which demonstrated a ballooned, foamy appearance.
Figure 3 Arterial administration of lipiodol-epirubicin before
surgical resection. Histological section of the tumour (silver
nitrate impregnation and haematoxylin and eosin stain) demon-
strates lipiodol within the lumina of tumour vessels (a), and areas
of necrosis around the vessels (b). Note the concentration of
lipiodol in the vascular endothelium (c).F-WIMM Cellular uptake in lipiodol
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Figure 4 HCC in explant liver arterially perfused with lipiodol
immediately after removal. Silver impregnation and haematoxylin
and eosin stain (a) shows lipiodol inside tumour cells, which have
a swollen, ballooned appearance. Transmission electron micro-
graphs show silver-impregnated black droplets of lipiodol in the
lumen of a tumour vessel and within the endothelial cell (b) and
droplets of lipiodol within the cytoplasm of a tumour cell (c).
Intracellular lipiodol was also present in the endothelial
cells lining the tumour vessels (Figure 4). The fact that the
lipid was found to have penetrated into tumour cells even
in an HCC that was fixed in 10% formaldehyde within 15
min of perfusion, suggests that entry of lipiodol into cells
is a rapid and possibly active process.
Discussion
After injection of lipiodol into the hepatic artery, embolisa-
tion of lipid droplets in tumour vasculature may well be the
initial event, but the findings of this study indicate that
lipiodol then penetrates into liver tumour cells and
endothelial cells, possibly by pinocytosis. At least in vitro
this does not appear to have any deleterious effect on cell
viability and replication. It is possible, using computer-
assisted image analysis, to quantitate lipiodol uptake in cell
monolayers, and uptake is related to the concentration of
lipiodol in the medium and also to the cell type. The different
patterns of lipiodol uptake in Hep G2 and HUVECs (Figure
2) raise the possibility of a synergistic mechanism in vivo
whereby endothelial cells may take up the oil from the vessel
lumen and disgorge it into the extravascular space from
where tumour cells proceed to incorporate it. However, these
are preliminary data from an in vitro situation, and further in
vivo dynamic studies would be required to establish these
mechanisms.
The incorporation of lipiodol by tumour cells raises
exciting therapeutic possibilities and indicates an urgent
need for iodised oil and other lipids to be evaluated further
as vehicles for cytotoxic agents. Lipiodol is not unique in this
respect, and selective uptake of other lipids such as linoleic
acid, olive oil, tea seed oil and medium-chain triglyceride by
liver tumours has been demonstrated in an animal model
(Iwai et al., 1987). If entry into the tumour cells can be
assured, then other isotopes such as 1251 may be considered in
preference to 1311 as a lipiodol conjugate. Also, linoleic and
arachidonic acid have been shown in in vitro studies to inhibit
the growth of cancer cells (Hussey and Tisdale, 1994), and
gamma-linoleic acid has been shown to enhance the effect of
anticancer treatments (Mudan et al., 1993); linoleic and
arachidonic acids are major constituents of lipiodol. Lipiodol
is known to localise in human kidney, breast and bladder
cancers; further studies are indicated to assess if cellular
incorporation of lipiodol occurs in these tumours as well.
Finally, the retention of lipiodol by endothelial cells in HCCs
suggests a potential role for it in targeting tumour
endothelium.
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